U.S. Banks Stock News

NasdaqGS:CTKB
NasdaqGS:CTKBLife Sciences

Can Cytek Biosciences' (CTKB) Steady Outlook Offset Its Shift to Losses?

Earlier this month, Cytek Biosciences reported third-quarter 2025 earnings, showing revenue of US$52.29 million and a net loss of US$5.48 million compared to net income in the prior year, and reaffirmed its full-year revenue guidance of US$196 million to US$205 million. This combination of improved quarterly revenue but a swing to quarterly and year-to-date losses provided investors with contrasting signals about Cytek’s ongoing financial health and outlook. We’ll review how the...
NasdaqGS:AUTL
NasdaqGS:AUTLBiotechs

A Fresh Look at Autolus Therapeutics (AUTL) Valuation Following Earnings, Obe-cel Expansion, and Anticipated ASH Data

Autolus Therapeutics (AUTL) just released its latest quarterly earnings and is drawing increased investor attention thanks to several key developments. The company continues to expand commercial access for Obe-cel, reports strong manufacturing results, and anticipates new data at the upcoming ASH conference. See our latest analysis for Autolus Therapeutics. Autolus Therapeutics has seen a burst of activity lately, from broadening commercial access and updating its leadership team to advancing...